Combining anti-metabolic treatments with the repurposing of eribulin for glioblastoma: a clinical opportunity?
Bibliographic record
Abstract
Glioblastoma (GBM) can either develop de novo or through progression from clinically silent low-grade gliomas or diffuse infiltrating astrocytomas, which usually develop throughout childhood and slowly expand through young adulthood.In most cases, this devastating disease has a high risk of recurrence and morbidity, which mostly affects young adults (1,2).Aggressive treatment typically involves initial maximal surgical resection, followed by radiotherapy with concomitant and maintenance temozolomide (TMZ), in combination with bevacizumab (3).However, once developed, the infiltrative and recurrent nature of GBM accounts for post-chemo/radiotherapy failures and a short median survival (less than 15 months) (1-3).Consequently, there is an urgent need to develop new therapies to improve the survival and the quality of life of GBM patients.In their recent study, Alcântara et al. studied the impact of eribulin on glioma and GBM cells (4).Eribulin is a drug commonly used for breast cancer chemotherapy (5).This drug is known to efficiently inhibit microtubule polymerization in numerous cancer cells, and the authors tested if it could be repurposed for GBM treatment.To this end, they used several cell lines in vitro, including HOG, T98G, U87MG, U251MG, and U138MG.While low nM concentrations of eribulin were highly efficient in some cell lines, reducing, for example, cell viability <95% in HOG cells, heterogeneity was observed with some cell
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.007 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.001 | 0.002 |
| Scholarly communication | 0.002 | 0.002 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.020 | 0.016 |
| Insufficient payload (model declined to judge) | 0.005 | 0.003 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".